Abattis Bioceuticals (Abattis Bioceuticals) LT-Debt-to-Total-Asset : 0.01 (As of Sep. 2019)

View and export this data going back to . Start your Free Trial

What is Abattis Bioceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Abattis Bioceuticals's long-term debt to total assests ratio for the quarter that ended in Sep. 2019 was 0.01.

Abattis Bioceuticals's long-term debt to total assets ratio increased from Sep. 2018 (0.00) to Sep. 2019 (0.01). It may suggest that Abattis Bioceuticals is progressively becoming more dependent on debt to grow their business.

Abattis Bioceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for Abattis Bioceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abattis Bioceuticals LT-Debt-to-Total-Asset Chart

Abattis Bioceuticals Annual Data

Trend

Sep10

Sep11

Sep12

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.03

0.01

Abattis Bioceuticals Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	0.01

Abattis Bioceuticals LT-Debt-to-Total-Asset Calculation

Abattis Bioceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2019 is calculated as

LT Debt to Total Assets (A: Sep. 2019 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2019 )	/	Total Assets (A: Sep. 2019 )
	=	0.094	/	14.546
	=	0.01

Abattis Bioceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2019 is calculated as

LT Debt to Total Assets (Q: Sep. 2019 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2019 )	/	Total Assets (Q: Sep. 2019 )
	=	0.094	/	14.546
	=	0.01

Abattis Bioceuticals (OTCPK:ATTBF) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Abattis Bioceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Abattis Bioceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Abattis Bioceuticals (Abattis Bioceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Abattis Bioceuticals Corp (OTCPK:ATTBF) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

1200 - 625 Howe Street, Vancouver, BC, CAN, V6C 2M6

Website

http://www.abattis.com

Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The company is also engaged in growing, extraction, testing, propagation and online distribution.